Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDP571
- Development stage
- Discontinued
- Lead developer
- UCB
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDP571 is a humanized monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a protein involved in systemic inflammation. It was developed for the treatment of inflammatory conditions, particularly Crohn's disease. Clinical trials showed modest effectiveness for short-term treatment of Crohn's disease, with better responses observed in patients with elevated baseline C-reactive protein levels.
- Other names
- Humicade
02
Targets
Beyond the preview
Go deeper on CDP571.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDP571.